Company intelligence / Profile preview

AnnJi Pharmaceutical Co., Ltd.

Ownership: Public · 7754
Development stage: Phase 1

Overview

AnnJi has demonstrated promising early clinical results. AJ101 showed significant reduction in inflammatory acne lesions in global Phase 1/2 studies. AJ201 is in a first-in-patient Phase 1/2a trial for Kennedy’s Disease/SBMA, with orphan drug designations granted by the FDA and EMA. Other assets are advancing toward or entering clinical trials for CIPN and IPF/fibrosis.

Therapeutic areas: DermatologyPulmonologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

rosolutamide

3 more assets in the full pipeline.

Request access →

Partnerships

Avenue Therapeutics – licensing agreement for development/commercialization of AJ201 in Kennedy’s Disease/SBMA; includes equity stake, milestone payments up to $250M plus royalties. Manufacturing rights retained by AnnJi.

Beyond the preview

Go deeper on AnnJi Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnnJi Pharmaceutical Co., Ltd..

Explore the full profile